Dangerous patients: what can you do?

Article

Q It seems that my patients are becoming larger, stronger, and more belligerent. Recently, a number of patients 9 to 16 years of age became uncooperative and actually combative when we performed procedures such as fingersticks for hemoglobin tests or administered vaccines.

Recent Videos
Contemporary Pediatrics: RX Review: Updates and Unmet Need in RSV thumbnail
Contemporary Pediatrics: RX Review: Updates and Unmet Need in RSV thumbnail
Contemporary Pediatrics: RX Review: Updates and Unmet Need in RSV thumbnail
Staphylococcus aureus risk in infants and neonatologist considerations with Aaron Milstone, MD
How fragrance plays a role in atopic dermatitis treatments, with John Browning, MD
Octavio Ramilo, MD, reacts to the FDA approval of clesrovimab for RSV prevention | Image Credit: St. Jude Children's Research Hospital
Related Content
Addictive screen use tied to youth mental health risks | Image Credit: © Yevhen - stock.adobe.com.

Addictive screen use tied to youth mental health risks

Morgan Ebert, Managing Editor
June 19th 2025
Article

Addictive use of screens—not total time—was linked to higher risks of suicidal behavior and mental health issues in early adolescents.

Site Logo

Food Insecurity and the Dangers of Infant Formula Dilution

January 30th 2023
Podcast
FDA approves lenacapavir as PrEP for HIV in adults, adolescents weighing at least 35 kg | Image Credit: Contemporary Pediatrics

FDA approves twice-yearly lenacapavir as PrEP for HIV in adolescents, adults

Joshua Fitch, Senior Editor
June 18th 2025
Article

Lenacapavir is the first twice-yearly option available in the US for those who need or want PrEP, according to Gilead Sciences.

Demystifying Infant Formula

Demystifying Infant Formula

October 11th 2022
Podcast
Phase 3 trial of omaveloxolone to treat Friedreich ataxia in children aged 2 to <16 begins | Image Credit: © 125154153 - stock.adobe.com.

Phase 3 trial of omaveloxolone to treat Friedreich ataxia in children aged 2 to <16 begins

Joshua Fitch, Senior Editor
June 18th 2025
Article

Currently, omaveloxolone (Skyclarys) is approved to treat adults and adolescents aged 16 years and older impacted by FA.

AAP issues updated guidance on contraception for adolescents | Image Credit: © New Africa - stock.adobe.com.

AAP updates guidance on contraception for adolescents

Morgan Ebert, Managing Editor
June 18th 2025
Article

The American Academy of Pediatrics urges clinicians to offer confidential, adolescent-centered contraceptive care using evidence-based, equity-informed approaches.

© 2025 MJH Life Sciences

All rights reserved.